Baxter sells injectibles to Hikma for $112M; Roche cleans up NJ site;

 @FierceBiotech: Pfizer's lung cancer drug crizotinib shows early promise. Report | Follow @FierceBiotech

Slideshow: Notorious Names in Biopharma. Slideshow

Special Report: Top 10 Women in Biotech. Article

Special Report: Pharma's Biggest Flops. Report

> Baxter will divest its U.S. generic injectibles business to Hikma Pharmaceuticals, a move worth approximately $112 million. The move includes 750 workers, a New Jersey manufacturing facility and Tennessee warehouse and distribution center. Baxter release*

> Roche tore down a Hoffman-Roche plant in Belleville, NJ, the first step in cleaning up 18.71 acres of contaminated land. Some of the contamination goes back to the 1800s and the copper mill formerly on the site. Article

> PharmAthene hopes to raise $15 million in a registered public offering. The company--with the offering's underwriter, Roth Capital Partners--will sell 4.3 million shares of stock for $3.50 per share. PharmAthene release

> StemCells, a Palo Alto, CA-based company, has started its second neuronal ceroid lipofuscinosis (Batten disease). The six-patient trial will test the efficacy of the company's HuCNS-SC product, created with purified human neural stem cells. Item

> The Centers for Disease Control and Prevention's vaccine advisors are considering whether to recommend that boys get the human papillomavirus vaccine as well as girls. It's the second time CDC officials have weighed the vaccine's value for boys, and the experts just can't decide whether preventing genital warts--the approved use for males--is worth the expense. Article

And Finally... The word is now out: Pharma whistleblower suits pay big. Just ask Cheryl Eckard, a former QA manager at GlaxoSmithKline who helped prosecutors build their case against the drug giant's Puerto Rican subsidiary for making and selling adulterated drugs. Her cut of the settlement is $96 million. Story

Editor's note: This item incorrectly stated that Pfizer, not Roche, tore down the site.

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.